Terms: = Sarcomas AND Neurokinin
7 results:
1. The Potential In Vitro Inhibitory Effects of neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis.
Alsaeed MA; Ebrahimi S; Alalikhan A; Hashemi SF; Hashemy SI
Biomed Res Int; 2022; 2022():8082608. PubMed ID: 36177059
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial.
Xiong J; Zhao G; Yang S; Chen J
Adv Ther; 2019 Feb; 36(2):355-364. PubMed ID: 30607545
[TBL] [Abstract] [Full Text] [Related]
3. Aprepitant for the Treatment of Chronic Refractory Pruritus.
He A; Alhariri JM; Sweren RJ; Kwatra MM; Kwatra SG
Biomed Res Int; 2017; 2017():4790810. PubMed ID: 29057261
[TBL] [Abstract] [Full Text] [Related]
4. Targeting neurokinin-3 receptor: a novel anti-angiogenesis strategy for cancer treatment.
Wang T; Chen S; Wang S; Shi L; Wang C; Zhang J; Gao Y; Li G; Qi Y; An X; Chen L
Oncotarget; 2017 Jun; 8(25):40713-40723. PubMed ID: 28489574
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract] [Full Text] [Related]
6. Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts.
Muñoz M; Berger M; Rosso M; Gonzalez-Ortega A; Carranza A; Coveñas R
Int J Oncol; 2014 Jan; 44(1):137-46. PubMed ID: 24190675
[TBL] [Abstract] [Full Text] [Related]
7. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
Howell JE; Szabatura AH; Hatfield Seung A; Nesbit SA
J Oncol Pharm Pract; 2008 Sep; 14(3):157-62. PubMed ID: 18719071
[TBL] [Abstract] [Full Text] [Related]